Fig. 6From: A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)Caregiver Global Impression-Change, any improvement: ≥ 90% methylation group. Percentage of patients who recorded improvements in Caregiver Global Impression-Change. The data represent results from the patients who had ≥ 90% methylation of the promoter region of the FMR1 geneBack to article page